Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy

By Marshall John   McEachern Kerry   Chuang Wei-Lien   Hutto Elizabeth   Siegel Craig   Shayman James   Grabowski Greg   Scheule Ronald   Copeland Diane   Cheng Seng  

Journal of Inherited Metabolic Disease, Vol. 33, Iss. 3, 2010-06 ,pp. : 281-289

Springer Publishing Company

Access to resources Recommend Favorite

A model of neuronopathic Gaucher disease

By Campbell P. E.   Campbell P. E.   Campbell P. E.   Harris C. M.   Harris C. M.   Sirimanna T.   Vellodi A.  

Journal of Inherited Metabolic Disease, Vol. 26, Iss. 7, 2003-01 ,pp. : 629-639

Springer Publishing Company

Access to resources Recommend Favorite

TYPE I GAUCHER DISEASE IN CHILDREN WITH AND WITHOUT ENZYME THERAPY

By Dweck Altoon   Abrahamov Ayala   Hadas-Halpern Irith   Bdolach-Avram Tali   Zimran Ari   Elstein Deborah  

Pediatric Hematology and Oncology, Vol. 19, Iss. 6, 2002-09 ,pp. : 389-397

Informa Healthcare

Access to resources Recommend Favorite

Lessons learned from the development of enzyme therapy for Gaucher disease

By Barranger J.   O'Rourke E.  

Journal of Inherited Metabolic Disease, Vol. 24, Iss. 2, 2001-04 ,pp. : 89-96

Springer Publishing Company

Access to resources Recommend Favorite

Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts

By Aureli Massimo  

Journal of Inherited Metabolic Disease, Vol. 35, Iss. 6, 2012-11 ,pp. : 1081-1091

Springer Publishing Company

Access to resources Recommend Favorite